Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs Methotrexate in Severe Alopecia Areata
NCT07406204Phase 4Not yet recruiting
- Sponsor
- Hayatabad Medical Complex
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of tofacitinib oral solution in alopecia areata, alopecia totalis (AT) and alopecia universalis (AU) (2 arms), sponsored by Hayatabad Medical Complex. Primary endpoint: Severity of Alopecia Tool at 12 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
alopecia areataalopecia totalis (AT)alopecia universalis (AU)
Beyond the preview
Go deeper on NCT07406204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406204.